LONDON, June 15, 2020 (GLOBE NEWSWIRE) -- Treos Bio Limited, a clinical stage biopharma company developing targeted peptide cancer immunotherapies, today said that it has developed and successfully tested in silico a preventive COVID-19 peptide vaccine and has transferred all rights, including pending patent applications, to a newly formed subsidiary, PepTC Vaccines Limited.
Treos developed this preventive vaccine product, PolyPEPI-SCoV-2, using its proprietary, computational vaccine design technology.
PepTC Vaccines’ PolyPEPI-SCoV-2 investigative vaccine is designed to elicit long-term T cell immunity in contrast to most of the vaccine candidates being developed with antibodies. It consists of 10 different, 30-amino acid long synthetic peptides. Read More